Scathing assessment of CIRM in report demonstrates stem cell challenges

We've written about the work of California Institute for Regenerative Medicine (CIRM) before but a detailed analysis and reporting by KQED didn't mince any words about the challenges CIRM is facing as it's beginning to run out of money without much to show for.

The article previews the goal of CIRM to go back to California voters in 2020 and ask for an additional $5 billion in taxpayer-funded bonds to continue the stem cell agency's work to find cures for various diseases and disorders.  

In the field of Spinal Cord Injury, the only clinical trial currently underway is the Asterias Biotherapeutics study which we have previously written about.